Clinical Trial Update: PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer [Phase 1]

View source ↗

Summary

This report covers a Phase 1 trial of PEG-interferon alfa-2b in combination with sorafenib for unresectable or metastatic kidney cancer. The study was terminate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Cancer

Drugs mentioned

• Peginterferon alfa-2b (Peginterferon alfa-2b)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Thomas Olencki | Conditions: Kidney Cancer | Phase 1 | Status: TERMINATED | Results posted: 2015-06-08